Zydus Cadila launched Ujvira, the first antibody drug conjugate (ADC)
Zydus Cadila launched Ujvira, a drug used for the treatment of breast cancer.
The company has launched the first antibody-drug conjugate (ADC) biosimilar and very effective medicine for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira, Zydus Cadila.
The drug is being offered at Rs 32,495 for a 100 mg vial.
Zydus Cadila said HER2 positive breast cancer is measured in an antagonistic form and founds 20 to 25 percent of all breast cancers. Trastuzumab Emtansine ADC biosimilar is a developmental finding due to its difficulty in manufacturing and parallel assays.